Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4799302
Max Phase: Preclinical
Molecular Formula: C36H41N3O8S
Molecular Weight: 675.80
Molecule Type: Unknown
Associated Items:
ID: ALA4799302
Max Phase: Preclinical
Molecular Formula: C36H41N3O8S
Molecular Weight: 675.80
Molecule Type: Unknown
Associated Items:
Canonical SMILES: COc1ccc(C[C@H](NS(=O)(=O)c2ccc(C)cc2)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](CC(C)C)C(=O)c2ccco2)cc1
Standard InChI: InChI=1S/C36H41N3O8S/c1-23(2)20-30(34(41)33-6-5-19-47-33)37-35(42)31(21-25-9-13-27(40)14-10-25)38-36(43)32(22-26-11-15-28(46-4)16-12-26)39-48(44,45)29-17-7-24(3)8-18-29/h5-19,23,30-32,39-40H,20-22H2,1-4H3,(H,37,42)(H,38,43)/t30-,31-,32-/m0/s1
Standard InChI Key: MZBQGKNMZPKPJB-CPCREDONSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 675.80 | Molecular Weight (Monoisotopic): 675.2614 | AlogP: 4.33 | #Rotatable Bonds: 16 |
Polar Surface Area: 164.04 | Molecular Species: NEUTRAL | HBA: 8 | HBD: 4 |
#RO5 Violations: 1 | HBA (Lipinski): 11 | HBD (Lipinski): 4 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: 9.44 | CX Basic pKa: | CX LogP: 5.21 | CX LogD: 5.21 |
Aromatic Rings: 4 | Heavy Atoms: 48 | QED Weighted: 0.13 | Np Likeness Score: -0.50 |
1. Sun Q,Zhou T,Xi D,Li X,Lü Z,Xu F,Wang C,Niu Y,Xu P. (2020) Design and synthesis of tripeptidyl furylketones as selective inhibitors against the β5 subunit of human 20S proteasome., 192 [PMID:32146375] [10.1016/j.ejmech.2020.112160] |
Source(1):